JeanMarie Guenot Gets Results At The Bank And In The Lab

 

JeanMarie Guenot, Ph.D., has an impressive career spanning more than 20 years and involving both business and science specialties. Dr. Guenot’s leadership helps build companies in biotechnology and pharmaceutical industries. Her scientific accomplishments include the discovery and development of medicines used to treat a range of conditions, especially cancer. Several companies have gained advantages from partnering with Dr. Guenot by garnering substantial financial strength or making strides in pharmaceutical development.

 

According to Dr. Guenot’s biography, posted on her official website, she began her business pursuits at a venture capital firm specializing in life science companies. She assisted with early stage financing for start-ups in the field and managed venture capital investments for the firm. From there, Dr. Guenot excelled at a range of business development tasks starting with venture capital procurement, then assisting with project and corporate development, allegiance creation and pharmaceutical research advancement. One of her outstanding achievements is the collaboration that brought together three drug candidates in an $8 million transaction. Dr. Guenot also created her own start-up incubator, SKS Ocular, for ophthalmic companies devoted to finding treatments and treatment methods for glaucoma, macular degeneration and other ocular concerns. Her success has enabled Dr. JeanMarie Guenot to receive both the BioBusiness Network’s Innovative Bio-Partnering Award and the Licensing Executives Society’s Deal of Distinction Award.

 

Dr. Guenot was president and chief executive officer of the drug development company, Amphivena Therapeutics when Amphivena partnered with Janssen Biotech, Inc. in 2015. The companies planned to develop new treatments for hematologic malignancies, or blood cancers, such as leukemia. An article in Marketwired dated April 7, 2015, states the partnership yielded results earlier than expected. This collaboration is only one example of how entities associated with Dr. JeanMarie Guenot have assisted partners in the development of innovative oncology, autoimmune disease, inflammation, cardiovascular disease and other therapies and treatments. Dr. Guenot’s career path is backed by her education as she earned an MBA from the University of Pennsylvania’s Wharton School, followed by a Ph.D. from the University of California thus equipping her with the knowledge she needed to excel not only in business development but also the biotechnology industry.

Kyle Bass: Investments That Harm Lives

Kyle Bass is the founder of Hayman Capital Management located in Dallas. His company is a hedge fund focusing on global opportunities. After he launched this hedge fund, he became big in the financial services industry because he successfully predicted information about the mortgage crisis.

Concerns are raised about hedge funds because they pose a challenge to drug patents that intend to gain money by purposefully dragging stock market prices down. Kyle Bass tried to eliminate drug patents; he says that larger companies try to extend the patent by changing the dosage or packaging, and in turn this keeps the drug prices high. This makes it extremely hard for the consumer to get their medications.

As time went on, Kyle Bass has made multiple negative career choices that made his untrustworthy. The more he puts himself on the media, the more his performance quality decreases. Bass tends to side with those who do not know what they are doing with their economic investments. He also tried to shift blame whenever possible. For General Motors, he goes on the media to shift the blame; instead of GM taking the blame for their non-deploying airbags and faulty power steering, Bass helps them blame those who died because of these issues. He claims that the victims were drunk or didn’t wear their seat belts properly.

Another large mistake that Kyle Bass has made is in line with pharmaceutical firms. He picks certain firms and short-sells their stocks. After that, he challenges them against the Coalition for Affordable Drugs, causing the stocks to go down. When the stocks go down, the prices go up. The bad part in this is that they have less to invest in medical research, which hurts millions of people. These people rely on these firms to help with their pain, but for Kyle Bass, it just rakes in money for himself.